BOSTON (MarketWatch) -- Shares of Dendreon Corp. /quotes/zigman/83175/quotes/nls/dndn DNDN -18.04% plunged 18% to $12.12 on Monday after it issued a weaker-than-expected quarterly sales report for its prostate cancer therapy Provenge. Dendreon shares have been on a roll since early January, when the stock soared almost 50% on stronger-than-expected sales for the therapy. Despite Monday's plunge, Dendreon's shares are still up nearly 60% for the year.
follow the right path for success, page-8
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.015(5.08%) |
Mkt cap ! $450.3M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 35.0¢ | 31.0¢ | $2.508M | 7.793M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 226373 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 40135 | 2 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |